Side-by-side · Research reference
SelankvsTesamorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft11/40 cited
BFDA-ApprovedVerified27/68 cited
Selank
Anxiolytic + Cognitive · Russian Pharma
Intranasal · 2–3×/day during stress / cognitive demand
Tesamorelin
GHRH Analogue · FDA-Approved
SQ · Abdomen · Once Daily
01Mechanism of Action
Parameter
Selank
Tesamorelin
Primary target
Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014
Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010
Pathway
Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007
GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007
Downstream effect
Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007Zaderej 2014
Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010
Feedback intact?
No GABA-receptor binding; no dependence reportedMedvedev 2007
Yes — physiological pulsatility preserved
Origin
Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014
Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010
02Dosage Protocols
Parameter
Selank
Tesamorelin
Standard dose
150–300 mcg / dose intranasalZaderej 2014
2 mg / dayEGRIFTA® (tesamorelin for inje 2010
FDA-approved protocol.
Frequency
2–3× per day during stress
Once daily (morning or pre-sleep)
Aligns with natural GH pulse.
Lower / starter dose
75 mcg / dose
1 mg / dayFalutz 2010
1 mg still produces significant IGF-1 elevation.
Evidence basis
Human-mechanistic + Russian clinical trialsMedvedev 2007
RCT / FDA-approvedFalutz 2007Falutz 2010
Duration
10–14 day cycles, repeated as needed
12–52 weeks
VAT returns within months of stopping.
Reconstitution
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Sterile water per labeling
Preserved at 2–8 °C after reconstitution.
Timing
Morning + early afternoon preferred
Empty stomach, pre-sleep preferred
Half-life
Short (minutes plasma); CNS effect lasts ~3 hr
~26 min (plasma)EGRIFTA® (tesamorelin for inje 2010
Modified vs native GHRH (7 min t½).
03Metabolic / Fat Loss Evidence
Parameter
Selank
Tesamorelin
Primary fat target
—
Visceral adipose tissue (VAT) — abdominal
Effect on lean mass
—
Modest lean mass preservation / slight increase
Effect reversibility
—
VAT returns within months of stopping
Key publication
—
Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007Falutz 2010EGRIFTA® (tesamorelin for inje 2010
04Side Effects & Safety
Parameter
Selank
Tesamorelin
Nasal irritation
Mild burning or congestion (transient)
—
Cognitive impairment
None — opposite effect (enhancement)
—
Allergic reaction
Rare hypersensitivity
—
Long-term safety
Limited Western RCT data
—
Injection site reaction
—
Erythema, pruritus, redness (common)
Fluid retention / Edema
—
Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)
IGF-1 elevation
—
Dose-dependent; supraphysiological levels = discontinue
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010
Antibody formation
—
~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018
GI symptoms
—
Nausea, diarrhea (mild, transient)
Absolute Contraindications
Selank
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
Tesamorelin
- ·Active malignancy or history of treated cancer
- ·Pregnancy
- ·Hypersensitivity to tesamorelin or mannitol
- ·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)
Relative Contraindications
Selank
- ·Active autoimmune disease (theoretical via immunomodulation)
Tesamorelin
- ·Untreated diabetes (monitor HbA1c)
- ·Severe carpal tunnel syndrome
- ·Acute critical illness
05Administration Protocol
Parameter
Selank
Tesamorelin
1. Form
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.
2. Administration
Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.
Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.
3. Timing
Morning + early afternoon for cognitive demand; PRN for acute anxiety.
Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.
4. Storage
Refrigerate after reconstitution; ≤30 days. Light-protected.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.
5. Caveat
Avoid co-administration with strong sedatives or other anxiolytics initially.
27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.
06Stack Synergy
Selank
— no documented stacks
Tesamorelin
+ Ipamorelin
StrongTesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.
- Tesamorelin
- 2 mg SQ · evening
- Ipamorelin
- 200–300 mcg SQ · same injection
- Frequency
- Once daily, pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep quality